Postocclusive reactive hyperemia inversely correlates with urinary 15-F2t-isoprostane levels in systemic sclerosis

Free Radical Biology and Medicine

Volumn 40, Issue 10, 2006, Pages 1732-1737

  Cracowski, Jean Luc ^a,b   Kom, Ghainsom D ^c   Salvat Melis, Muriel ^a,b   Renversez, Jean Charles ^b   McCord, Gregg ^d   Boignard, Aude ^a   Carpentier, Patrick H ^b   Schwedhelm, Edzard ^c  

^a University Grenoble Alpes   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY OF OREGON   (United States)

Author keywords

Free radicals; Isoprostane; Microcirculation; Oxidative stress; Raynaud's phenomenon; Systemic sclerosis; Vasodilation

Indexed keywords

GLYCERYL TRINITRATE; ISOPROSTANE DERIVATIVE;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM LESION; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HYPEREMIA; LASER DOPPLER FLOWMETRY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MEDICAL ASSESSMENT; MICROVASCULAR ISCHEMIA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RAYNAUD PHENOMENON; SAMPLE SIZE; SYSTEMIC SCLEROSIS;

DINOPROST; HUMANS; HYPEREMIA; INTERLEUKIN-1; INTERLEUKIN-6; LASER-DOPPLER FLOWMETRY; LIPID PEROXIDATION; MICROCIRCULATION; OXIDATIVE STRESS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SKIN;

EID: 33646134594     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2006.01.014     Document Type: Article

References (27)

1. Herrick A.L. Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford) 44 (2005) 587-596
2. Wigley F.M., Wise R.A., Mikdashi J., Schaefer S., and Spence R.J. The post-occlusive hyperemic response in patients with systemic sclerosis. Arthritis Rheum. 33 (1990) 1620-1625
3. Boignard A., Salvat-Melis M., Carpentier P., Minson C., Grange L., Duc C., Sarrot-Reynauld F., and Cracowski J. Local hyperemia to heating is impaired in secondary Raynaud's phenomenon. Arthritis Res. Ther. 7 (2005) R1103-R1112
4. Rajagopalan S., Pfenninger D., Kehrer C., Chakrabarti A., Somers E., Pavlic R., Mukherjee D., Brook R., D'Alecy L.G., and Kaplan M.J. Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease. Arthritis Rheum. 48 (2003) 1992-2000
5. Wollersheim H., Reyenga J., and Thien T. Postocclusive reactive hyperemia of fingertips, monitored by laser Doppler velocimetry in the diagnosis of Raynaud's phenomenon. Microvasc. Res. 38 (1989) 286-295
6. Cracowski J.L. Isoprostanes: an emerging role in vascular physiology and disease? Chem. Phys. Lipids 128 (2004) 75-83
7. 2-isoprostanes as an index of oxidative stress in vivo. Free Radic. Biol. Med. 28 (2000) 505-513
8. Cracowski J.L., Durand T., and Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol. Sci. 23 (2002) 360-366
9. Stein C.M., Tanner S.B., Awad J.A., Roberts L.J., and Morrow J.D. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum. 39 (1996) 1146-1150
10. Cracowski J.L., Marpeau C., Carpentier P.H., Imbert B., Hunt M., Stanke-Labesque F., and Bessard G. Enhanced in vivo lipid peroxidation in scleroderma spectrum disorders. Arthritis Rheum. 44 (2001) 1143-1148
11. Cracowski J.L., Carpentier P.H., Imbert B., Cachot S., Stanke-Labesque F., Bessard J., and Bessard G. Increased urinary F2-isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenon: effect of cold exposure. Arthritis Rheum. 46 (2002) 1319-1323
12. Volpe, A.; Biasi, D.; Caramaschi, P.; Mantovani, W.; Bambara, L. M.; Canestrini, S.; Ferrari, M.; Poli, G.; Degan, M.; Carletto, A.; Pieropan, S.; Minuz, P. Levels of F2-isoprostanes in systemic sclerosis: correlation with clinical features. Rheumatology (Oxford). Advance access published online, October 11, 2005.
13. LeRoy E.C., and Medsger Jr. T.A. Criteria for the classification of early systemic sclerosis. J. Rheumatol. 28 (2001) 1573-1576
14. Leroy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T.A., Rowell N., and Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 15 (1988) 202-205
15. Leroy E.C., and Medsger Jr. T.A. Raynaud's phenomenon: a proposal for classification. Clin. Exp. Rheumatol. 10 (1992) 485-488
16. Furst D.E., Clements P.J., Steen V.D., Medsger Jr. T.A., Masi A.T., D'Angelo W.A., Lachenbruch P.A., Grau R.G., and Seibold J.R. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J. Rheumatol. 25 (1998) 84-88
17. Tsikas D., Schwedhelm E., Suchy M.T., Niemann J., Gutzki F.M., Erpenbeck V.J., Hohlfeld J.M., Surdacki A., and Frolich J.C. Divergence in urinary 8-iso-PGF(2alpha) (iPF(2alpha)-III, 15-F(2t)-IsoP) levels from gas chromatography-tandem mass spectrometry quantification after thin-layer chromatography and immunoaffinity column chromatography reveals heterogeneity of 8-iso-PGF(2alpha): possible methodological, mechanistic and clinical implications. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 794 (2003) 237-255
18. Tsikas D., Schwedhelm E., Fauler J., Gutzki F.M., Mayatepek E., and Frolich J.C. Specific and rapid quantification of 8-iso-prostaglandin F2alpha in urine of healthy humans and patients with Zellweger syndrome by gas chromatography-tandem mass spectrometry. J. Chromatogr. B Biomed. Sci. Appl. 716 (1998) 7-17
19. Herrick A.L. Vascular function in systemic sclerosis. Curr. Opin. Rheumatol. 12 (2000) 527-533
20. Kahaleh B., Meyer O., and Scorza R. Assessment of vascular involvement. Clin. Exp. Rheumatol. 21 (2003) S9-S14
21. Bircher A., de Boer E.M., Agner T., Wahlberg J.E., and Serup J. Guidelines for measurement of cutaneous blood flow by laser Doppler flowmetry: a report from the Standardization Group of the European Society of Contact Dermatitis. Contact Dermatitis 30 (1994) 65-72
22. Carpentier P.H. New techniques for clinical assessment of the peripheral microcirculation. Drugs 59 Spec. Issue (1999) 17-22
23. Schwedhelm E., Bartling A., Lenzen H., Tsikas D., Maas R., Brummer J., Gutzki F.M., Berger J., Frolich J.C., and Boger R.H. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 109 (2004) 843-848
24. Schwedhelm E., Tsikas D., Durand T., Gutzki F.M., Guy A., Rossi J.C., and Frolich J.C. Tandem mass spectrometric quantification of 8-iso-prostaglandin F2alpha and its metabolite 2,3-dinor-5,6-dihydro-8-iso-prostaglandin F2alpha in human urine. J. Chromatogr. B Biomed. Sci. Appl. 744 (2000) 99-112
25. 2α type III in human urine by gas chromatography-electronic impact mass spectrometry: comparison with enzyme immunoassay. J. Chromatogr. B 754 (2001) 333-343
26. Cracowski J.L., Girolet S., Imbert B., Seinturier C., Stanke-Labesque F., Bessard J., Boignard A., Bessard G., and Carpentier P.H. Effects of short-term treatment with vitamin E in systemic sclerosis: a double blind, randomized, controlled clinical trial of efficacy based on urinary isoprostane measurement. Free Radic. Biol. Med. 38 (2005) 98-103
27. 2-isoprostanes in patients with Crohn's disease. Am. J. Gastroenterol. 97 (2002) 99-103